<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04727242</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-56728</org_study_id>
    <secondary_id>SARCOMA0045</secondary_id>
    <nct_id>NCT04727242</nct_id>
  </id_info>
  <brief_title>CytoreductiveSurgery &amp; HIPEC w/Gemcitabine+Chemotherapy w/Dacarbazine in Uterine Leiomyosarcoma</brief_title>
  <official_title>Phase 2 Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Gemcitabine Followed by Systemic Adjuvant Chemotherapy With Dacarbazine for Locally Recurrent Uterine Leiomyosarcoma (LMS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if giving a dose of heated chemotherapy in the&#xD;
      abdomen immediately after surgery that is done to remove uterine leiomyosarcoma type of&#xD;
      cancer will help lower the risk of the cancer coming back in the future.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      - To assess the efficacy of cytoreductive surgery with gemcitabine HIPEC followed by&#xD;
      postoperative systemic chemotherapy with dacarbazine in subjects with locally recurrent&#xD;
      uterine LMS.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To assess the safety of cytoreductive surgery with gemcitabine HIPEC in subjects with&#xD;
           locally recurrent uterine LMS.&#xD;
&#xD;
        -  To assess the 6 month and 12 month intraabdominal relapse free survival in subjects with&#xD;
           locally recurrent uterine LMS&#xD;
&#xD;
        -  To determine quality of life prior to therapy (within 28 days prior to surgery with&#xD;
           HIPEC), 4 to 6 weeks after surgery with HIPEC, and then at Cycle&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 28, 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>1 year</time_frame>
    <description>Progression free survival as measured from the time of surgery until death or disease progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Grade 4 infections</measure>
    <time_frame>30 days post surgery with gemcitabine HIPEC</time_frame>
    <description>Rate of Grade 4 infections within 30 days post surgery with gemcitabine HIPEC will be assessed using CTCAE version 5.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraabdominal relapse free survival</measure>
    <time_frame>6 months</time_frame>
    <description>Relapse free survival as measured from time of surgery until intraabdominal recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraabdominal relapse free survival</measure>
    <time_frame>12 months</time_frame>
    <description>Relapse free survival as measured from time of surgery until intraabdominal recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Functional Assessment of Cancer Therapy: General (FACT G) score</measure>
    <time_frame>Baseline, 4 to 6 weeks post-surgery with HIPEC</time_frame>
    <description>Difference in overall FACT G score from baseline to 4 to 6 weeks post-surgery with gemcitabine HIPEC.&#xD;
FACT G is a quality of life questionnaire composed of 27 items divided into four main quality of life categories: Physical Well Being (PWB); Social/Family Well Being (SWB); Emotional Well Being (EWB); and Functional Well Being (FWB). Total FACT G score is obtained by summing the scores from the four main QoL categories (PWB; SWB; EWB; FWB). The range of the scale is 0-108. Negatively worded items are reverse scored prior to summing so that higher subscale and total scores indicate better Quality of life (Qol).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>LMS - Leiomyosarcoma</condition>
  <condition>Uterine Leiomyosarcoma</condition>
  <arm_group>
    <arm_group_label>Cytoreductive Surgery+HIPEC gemcitabine+dacarbazine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC) with gemcitabine followed by postoperative systemic chemotherapy with dacarbazine. Conceptually, HIPEC will be administered as a 60 minute heated intraperitoneal infusion (ie, intraperitoneal &quot;wash&quot; or &quot;lavage&quot;).&#xD;
HIPEC: Gemcitabine will be instilled at a dose of 1000 mg/m2 for 60 minutes at temperatures of 42° to 43°C.&#xD;
Systemic adjuvant chemotherapy starting 30 days ± 14 days post surgery. Dacarbazine 1000 mg/m2 IV every 3 weeks x 6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Hyperthermic intraperitoneal chemotherapy (HIPEC) with gemcitabine. Gemcitabine will be instilled at a dose of 1000 mg/m2 for 60 minutes at temperatures of 42° to 43°C.</description>
    <arm_group_label>Cytoreductive Surgery+HIPEC gemcitabine+dacarbazine</arm_group_label>
    <other_name>Gemzar</other_name>
    <other_name>Infugem</other_name>
    <other_name>difluorodeoxycytidine hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacarbazine</intervention_name>
    <description>Dacarbazine 1000 mg/m2 IV every 3 weeks x 6 cycles given IV</description>
    <arm_group_label>Cytoreductive Surgery+HIPEC gemcitabine+dacarbazine</arm_group_label>
    <other_name>Dimethyl (triazeno) imidazolecarboxamide</other_name>
    <other_name>Dacarbazine - DTIC</other_name>
    <other_name>Biocarbazine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cytoreductive Surgery</intervention_name>
    <description>Surgery for cancer removal</description>
    <arm_group_label>Cytoreductive Surgery+HIPEC gemcitabine+dacarbazine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Functional Assessment of Cancer Therapy (FACT) G questionnaire</intervention_name>
    <description>Preoperative and Postoperative FACT G questionnaire to assess QoL</description>
    <arm_group_label>Cytoreductive Surgery+HIPEC gemcitabine+dacarbazine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Scan</intervention_name>
    <description>Radiologic imaging after Cycle 3 and 6 and at each follow up visit</description>
    <arm_group_label>Cytoreductive Surgery+HIPEC gemcitabine+dacarbazine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gadolinium</intervention_name>
    <description>Contrast Agent</description>
    <arm_group_label>Cytoreductive Surgery+HIPEC gemcitabine+dacarbazine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed diagnosis of uterine leiomyosarcoma (LMS) with evidence of&#xD;
             local recurrence.&#xD;
&#xD;
          2. Imaging provides evidence of locally recurrent uterine LMS.&#xD;
&#xD;
          3. Candidate for potentially radical, maximal effort cytoreductive surgery at the&#xD;
             discretion and expertise of the treating physician.&#xD;
&#xD;
          4. Age ≥ 18 years.&#xD;
&#xD;
          5. Life expectancy &gt; 3 months.&#xD;
&#xD;
          6. Women of childbearing potential (WOCBP) will have a negative pregnancy test ≤ 7 days&#xD;
             prior to surgery (this test can be omitted if subject is post menopausal by either&#xD;
             surgery or elevated FSH)&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2.&#xD;
&#xD;
          8. Hemoglobin (HGB) ≥ 9 g/dL.&#xD;
&#xD;
          9. White blood cell count (WBC) ≥ 3.0 K/ul.&#xD;
&#xD;
         10. Absolute neutrophil count (ANC) ≥ 1.5 K/ul.&#xD;
&#xD;
         11. Platelets (PLT) ≥ 100 K/ul.&#xD;
&#xD;
         12. Total bilirubin within normal institutional limits.&#xD;
&#xD;
         13. Serum glutamic oxaloacetic transaminase (SGOT/Serum glutamic pyruvic transaminase&#xD;
             (SGPT) &lt; 2.5 x institutional upper limit of normal (ULN).&#xD;
&#xD;
         14. Creatinine &lt; 1.5 x ULN or creatinine clearance &gt; 60 mL/min according to Cockroft Gault&#xD;
             formula.&#xD;
&#xD;
         15. Prothrombin Time (PT) such that international normalized ratio (INR) is &lt; 1.5 (or an&#xD;
             in range INR, usually between 2 and 3, if a subject is on a stable dose of therapeutic&#xD;
             warfarin or low molecular weight heparin) and a partial thromboplastin time (PTT) &lt;&#xD;
             1.2 times control.&#xD;
&#xD;
         16. Serum albumin ≥ 2.5 g/dL.&#xD;
&#xD;
         17. Ability to understand and the willingness to personally sign the written IRB approved&#xD;
             informed consent document.&#xD;
&#xD;
        Note that this study does not allow the use of a legally authorized representative&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Recurrence of LMS within less than 6 months after the last dose of gemcitabine.&#xD;
&#xD;
          2. Active extra abdominal disease including active malignant pleural effusion. Subjects&#xD;
             who have been successfully treated with neoadjuvant chemotherapy and no longer have&#xD;
             (malignant) pleural effusions may be included.&#xD;
&#xD;
          3. Prior gemcitabine given in non adjuvant setting.&#xD;
&#xD;
          4. Prior treatment with dacarbazine.&#xD;
&#xD;
          5. Active infection requiring antibiotics.&#xD;
&#xD;
          6. Unresolved toxic effects of prior therapy (except alopecia). Resolution is considered&#xD;
             ≤ Grade 1 per NCI CTCAE, version 5.0.&#xD;
&#xD;
          7. Pregnant.&#xD;
&#xD;
          8. Breast feeding.&#xD;
&#xD;
          9. Presence of metastatic liver disease&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristen N Ganjoo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Ahern</last_name>
    <phone>650-725-6413</phone>
    <email>mahern@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Ahern</last_name>
      <phone>650-725-6413</phone>
      <email>mahern@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Kristen N Ganjoo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 22, 2021</study_first_submitted>
  <study_first_submitted_qc>January 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2021</study_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leiomyosarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

